NEW YORK – Massive Bio has partnered with Asklepieia Health Cluster, an organization focused on establishing Greece as a leading health tourism destination, to bring its clinical trial matching platform to the country.
New York-based Massive Bio said on Wednesday that it is also in talks to collaborate with BeStrong, a Greek nonprofit focused on providing cancer-related education and resources, and Open Health Alliance, a nonprofit medical network in Greece.
Asklepieia will use Massive Bio's clinical trial matching platform to identify patients who could benefit from investigational medicines in ongoing studies and introduce new trials that patients in Greece can take part in. BeStrong and Open Health Alliance will provide updated clinical trial information to physicians and facilitate faster patient enrollment through real-time support.
"Our collaboration with Asklepieia combines precision medicine with AI-driven clinical trial matching, speeding up the introduction of clinical trials in Greece," Massive Bio Chief Operating Officer Cagatay Culcuoglu said in a statement. "Our partnerships with BeStrong and Open Health Alliance will help us to enhance oncology and hematology cancer care through cutting-edge technologies, physician access, and patient advocacy, delivering more personalized care and advanced treatments."
Massive Bio's platform uses artificial intelligence to support clinical trial matching, therapy matching, and drug development. The firm has several ongoing partnerships with Azra AI, NeoGenomics, and CureMatch to provide clinical trial matching.